Key clinical point: Switching from low-dose to high-dose empagliflozin led to significant clinical benefits in patients with type 2 diabetes (T2D) and inadequate glycemic control.
Major finding: Increasing the dose of empagliflozin from 10 mg to 25 mg for 6 months significantly improved the fasting plasma glucose and glycated hemoglobin levels by −12.7 mg/dL and −13%, respectively ( P < .01), along with a significant reduction in body weight ( −0.6 kg), triglyceride level ( −22.1 mg/dL), and c-glutamyl transpeptidase level ( −6.6 U/L; P < .01) and increase in hematocrit by 0.9% after 3 months.
Study details: This was a retrospective study including 52 patients with T2D and inadequate glycemic control whose dose of empagliflozin was increased from 10 mg to 25 mg once daily.
Disclosures: This study was sponsored by Shimazu Corporation, Kyoto, Japan. The authors declared no conflicts of interest.
Source: Matsumura T et al. Clinical benefit of switching from low-dose to high-dose empagliflozin in patients with type 2 diabetes. Diabetes Ther. 2022 (Jul 15). Doi: 10.1007/s13300-022-01296-y